Neoleukin Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Seattle, dec. 14, 2023 (globe newswire) -- neoleukin therapeutics, inc., “neoleukin” or the “company” (nasdaq:nltx), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its board of directors (“board”) has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-4. the reverse stock split will become effective at 12:02 a.m., eastern time on december 18, 2023. the company's common stock is expected to begin trading on a post-reverse stock split basis on the nasdaq global market on december 19, 2023, under the new name neurogene inc. and under the new symbol "ngne" following the anticipated closing of the merger with neurogene inc...

Seattle, sept. 22, 2023 (globe newswire) -- neoleukin therapeutics, inc., “neoleukin” or the “company” (nasdaq:nltx), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its board of directors (“board”) has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-5. the reverse stock split will become effective at 12:01 a.m. eastern time on september 25, 2023. neoleukin's common stock will begin trading on a post-reverse stock split basis on september 25, 2023, under neoleukin's existing trading symbol “nltx” with a new cusip number 64049k203...

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of neoleukin therapeutics, inc. (nasdaqcm: nltx) with neurogene inc. under the terms of the proposed transaction, pre-merger neoleukin stockholders are expected to own approximately 16% of the combined company (subject to certain adjustments) and will also be issued contingent value rights to receive certain pa.

Milwaukee , july 18, 2023 /prnewswire/ -- ademi llp is investigating neoleukin (nasdaq: nltx) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with neurogene.  click here to learn how to join the action https://www.ademilaw.com/case/neoleukin-therapeutics-inc or call guri ademi toll-free at 866-264-3995.

New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of neoleukin therapeutics, inc. (nasdaq: nltx) and neurogene inc. is fair to neoleukin shareholders. pre-merger neoleukin stockholders are expected to own approximately 16% of the combined company. halper sadeh encourages neoleukin shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersade.

San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Financial), a biopharmaceutical company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of both Redmile Group and Neoleukin Therapeutics, and an evaluation of the latter's financial health and industry position.

Neoleukin Therapeutics: Strategic Review Play

Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.

Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday.

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Officer Priti Patel - Chief Medical Officer Sean Smith - Vice President, Finance Conference Call Participants Mary Kate - Bank of America Charles Zhu - Guggenheim Securities Ben Burnett - Stifel Mara Goldstein - Mizuho Securities Operator Good afternoon and thank you for joining us today for the Neoleukin Therapeutics Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows:

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2021 Results - Earnings Call Transcript